Table 3.
Cell viability IC50 values for KG-1, U-937, RAJI, PC-3, MDA-MB-231, RPMI1788, and non-proliferating or proliferating PBM cells after 48 h of treatment with MC3353 or SGI-1027
| Compound | IC50 ± SDa, μM (Selectivity indexb) | |||||||
|---|---|---|---|---|---|---|---|---|
| KG-1 | U-937 | RAJI | PC-3 | MDA-MB-231 | RPMI1788 | PBMCs | PHA_PBMCsc | |
| MC3353 | 0.3 ± 0.0 | 0.4 ± 0.0 | 0.4 ± 0.0 | 0.9 ± 0.4 | 0.9 ± 0.7 | 2.4 ± 0.2 | 8.9 ± 4.2 | 4.6 ± 0.5 |
| (IC50 RPMI1788/IC50 cell line) | (7.2) | (6.6) | (6.3) | (2.7) | (2.6) | (NA) | (NA) | (NA) |
| (IC50 PBMCs/IC50 cell line) | (26.2) | (24.0) | (23.1) | (9.8) | (9.7) | (NA) | (NA) | (NA) |
| (IC50 PHA_PBMCs/IC50 cell line) | (13.5) | (12.4) | (11.9) | (5.1) | (5.0) | (NA) | (NA) | (NA) |
| SGI-1027 | 3.6 ± 0.6 | 1.7 ± 1.5 | 7.8 ± 0.7 | 5.0 ± 0.6 | 8.5 ± 7.2 | 6.7 ± 1.3 | 18.1 ± 6.8 | ND |
| (IC50 RPMI1788/IC50 cell line) | (1.9) | (3.9) | (0.9) | (1.3) | (0.8) | (NA) | (NA) | (NA) |
| (IC50 PBMCs/IC50 cell line) | (5) | (10.6) | (2.3) | (3.6) | (2.1) | (NA) | (NA) | (NA) |
SD standard deviation, NA not applicable, ND not determined
aData are the mean of at least three independent experiments
bDifferential toxicity was calculated as the ratio of the IC50 normal cells (either PBMCs or RMPI1788) to the IC50 neoplastic cells
cPHA_PBMCs: phytohemagglutinin-stimulated PBMCs